Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,868,942 papers from all fields of science
Search
Sign In
Create Free Account
belinostat
Known as:
2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-
A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
11 relations
Angiogenesis Inhibition
Histone Deacetylase
NCIt Antineoplastic Agent Terminology
Positive Regulation of Apoptosis
Expand
Broader (4)
Antineoplastic Agents
Histone deacetylase inhibitor
Hydroxamic Acids
Sulfonamides
Narrower (1)
PXD101
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract 5480: Effects of UGT1A1 genotype on pharmacokinetics and toxicities of belinostat administered by continuous infusion in two clinical trials
A. Goey
,
T. Sissung
,
+8 authors
W. Figg
2015
Corpus ID: 78425996
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Background: Belinostat (B), a histone…
Expand
2014
2014
Pharmaceutical approval update.
M. Goldenberg
P & T : a peer-reviewed journal for formulary…
2014
Corpus ID: 43560710
Dapaglifozin (Farxiga) for improved glycemic control in type-2 diabetes, and trametinib (Mekinist) in combination with dabrafenib…
Expand
2013
2013
Investigating the synthetic lethal effects of poly (ADP-ribose) polymerase and histone deacetylase inhibition in progressive B-Cell chronic lymphocytic leukaemia deficient in the ATM pathway and…
D. Cartwright
2013
Corpus ID: 83083462
This thesis contains two research projects. The first contributed to the development of poly (ADP-ribose) polymerase inhibitors…
Expand
2012
2012
latent EBV and sensitize lymphoma cells to nucleoside antiviral agents Histone deacetylase inhibitors are potent inducers of gene expression in
S. Ghosh
,
S. Perrine
,
Robert M. Williams
,
D. Faller
2012
Corpus ID: 207790688
http://bloodjournal.hematologylibrary.org/content/119/4/1008.full.html Updated information and services can be found at: (1291…
Expand
2010
2010
Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma.
L. Wang
,
B. Goh
,
+5 authors
W. Yeo
2010
Corpus ID: 79433308
2585 Background: Metabolic inactivation of several hydroxamic acid-derived histone deacetylase inhibitors (HDACi) involves…
Expand
2010
2010
An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated…
G. Daugaard
,
K. Fizazi
,
+7 authors
J. Hainsworth
2010
Corpus ID: 77267798
TPS185 Background: Treatment options for patients (pts) with cancer of unknown primary (CUP) are limited; carboplatin (C) and…
Expand
2010
2010
Pharmaceutical approval update.
M. Goldenberg
P & T : a peer-reviewed journal for formulary…
2010
Corpus ID: 9794349
reactions occurring in 13% of patients or more, regardless of the cause, were vomiting, abdominal pain, pyrexia, tonsillitis…
Expand
2007
2007
A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocellular carcinoma
W. Yeo
,
R. Lim
,
+8 authors
Bo-On-Cher Goh
2007
Corpus ID: 77657573
15081 Background: Hepatocellular carcinoma (HCC) is a common cause of cancer morbidity and mortality. It is a highly aggressive…
Expand
2007
2007
Defining a set of genes dysregulated in response to the HDAC inhibitor PXD101 (belinostat)
R. Shoemaker
,
C. Hose
,
+4 authors
A. Monks
2007
Corpus ID: 88714717
A129 PXD101(NSC 726630) is a hydroxamate-type histone deactylase inhibitor (HDACi), which is a compound class emerging as…
Expand
1969
1969
Zinc-dependent Deacetylase (HDAC) Inhibitors with Different ZBG Groups
Yan Li
,
Fang Wang
,
+4 authors
Bin He
1969
Corpus ID: 222394917